With increasing excitement surrounding US tech stocks, UK shares have been somewhat overlooked, despite a number of promising performances among domestic companies. Since December 2024, numerous UK stocks have outperformed industry giants like Nvidia. Additionally, the FTSE 100 has experienced greater growth than the S&P 500 since the start of 2025, though this positive news has not received substantial media attention.
This somewhat muted reaction may stem from a cultural tendency toward modesty in Britain, despite the country’s significant contributions to global innovation, including advancements in computing, lithium-ion batteries, and the internet. The London Stock Exchange boasts a collection of impressive companies, notably pharmaceutical leader AstraZeneca.
Despite AstraZeneca’s market capitalization being nearly 94% lower than Nvidia’s, its stock performance over the past year has been commendable. The company is reportedly on track to achieve its goal of $80 billion in revenue by 2030, bolstered by encouraging results released for the nine months ending on September 30, which indicated an 11% revenue increase to $43.2 billion compared to the same period the previous year. Core earnings per share also rose by 15%, and the company has shown a strengthening balance sheet, with net debt decreasing by $2.38 billion year-on-year.
AstraZeneca has announced a record number of positive outcomes in Phase III trials—16 in total—marking significant progress in its drug development pipeline. These trials represent the final hurdle before potential approvals, indicating strong prospects for future earnings. However, the challenge of creating new medicines remains critical, particularly as the exclusivity periods for their new treatments can significantly impact revenues once they expire, paving the way for cheaper generic alternatives.
While AstraZeneca’s stock has reached record highs, it is valued at close to 30 times the forecasted earnings for 2025, prompting some concern over its pricing. Despite the company’s ongoing need to reinvest heavily in research and development, its dividend yield of 1.8% falls below the FTSE 100 average, making it relatively less attractive for income-focused investors.
In recent news, AstraZeneca and the broader UK pharmaceutical industry received a significant boost after it was confirmed that there would be no tariffs on UK medicine exports to the US. This development indicates a positive shift in international trade relations, alongside new commitments from the NHS to spend more on innovative drugs while also easing the rebate conditions placed on pharmaceutical companies once their revenues surpass expected levels. This change has been positively received by the Association of the British Pharmaceutical Industry, suggesting a favorable outlook for AstraZeneca as a key beneficiary.
Overall, while AstraZeneca stands out as a noteworthy stock in the UK market, it represents just one opportunity. Currently, UK stocks appear to be priced more attractively compared to their US counterparts, with many British companies offering higher dividend yields. For investors seeking new opportunities, it may be an opportune time to explore UK shares.
